Page 1

Ⓒ immunovia INTERIM REPORT JANUARY SEK thousand unless otherwise stated Net sales Operating earnings Earnings before tax Net earnings Earnings per share before dilution ( SEK ) Earnings per share before after dilution ( SEK ) Equity ratio ( % ) Number of shares at the end of the period - SEPTEMBER 2021 Key indicators 2021 Jul - Sep 377 -39,938 -36,131 -36,131 -1.60 -1.60 88 22,631,581 IMMUNOVIA AB Significant events July - September 2021 On August 3 , Immunovia Inc. received a clinical labo ratory licensure from the Massachusetts Department of Public Health . This means that Immunovia , Inc. has been approved , and now has begun , to sell its blood test for early detection of pancreatic cancer IMMrayTM PanCan - d in the USA , exclusively through the laboratory in Marl borough , Massachusetts . In August , Immunovia provided two updates regarding the IMMray ™ PanCan - d test . First , the test was launched at a list price of USD 995 per test . Second , the test was launched for those individuals with CA 19-9 levels grea ter than 2.5 U / ml . The overall sensitivity of the test then improves to 89 percent in stages I and II , and 92 percent in all stages . The specificity of the test is 99 percent for stage I & II . In September , Immunovia entered a license agreement with the South Korean company JW Bioscience for pan creatic cancer biomarkers to strengthen it's IP portfo lio . The license agreement secures Immunovia global commercial rights for two biomarkers in the IMMray ™ PanCan - d biomarker signature . Immunovia discovered these biomarkers independently of JW Bioscience and has now fully secured the intellectual property rights . Ⓡ 2020 Jul - Sep 37 -35,432 -38,064 -38,064 -1.68 -1.68 91 2021 Jan - Sep 539 -115,752 -108,838 -108,838 -4.81 -4.81 88 22,603,081 22,631,581 5700 2020 Jan - Sep EARLY DETECTION 210 -96,232 -99,914 -99,914 -4.78 -4.78 91 22,603,081 2020 Full year 362 -134,343 -146,033 -146,033 -6.84 -6.84 91 22,631,581 In September , Pancreatic Cancer Action Network ( PanCAN ) , which is one of the most influential patient advocacy groups in the USA , informed its constituents about Immunovia's IMMray ™ PanCan - d test on its web site , in their social media channels and through direct email contacts . A special training for the PanCAN's Patient Services team about the test has been performed for the team to be able to inform and answer incoming ques tions about the test . Significant events after the period In October , it was communicated that Karin Almqvist Liwendahl will join Immunovia as new Chief Financial Officer ( CFO ) at the latest by April 1st , 2022. Karin is an experienced CFO and Investor Relations professional with a background in the telecom and life sciences in dustries . Current CFO Hans Liljenborg will continue with Immunovia in the position as Finance Director .